Comprehensive analysis of germline variants in mexican patients with hereditary breast and ovarian cancer susceptibility
Hereditary breast and ovarian cancer syndrome (HBOC) represents 5–10% of all patients with breast cancer and is associated with high-risk pathogenic alleles in BRCA1/2 genes, but only for 25% of cases. We aimed to find new pathogenic alleles in a panel of 143 cancer-predisposing genes in 300 Mexican...
- Autores:
-
Quezada Urban, Rosalía
Díaz Velásquez, Clara Estela
Gitler, Rina
Rojo Castillo, María Patricia
Sirota Toporek, Max
Figueroa Morales, Andrea
Moreno García, Oscar
García Esquivel, Lizbeth
Torres Mejía, Gabriela
Dean, Michael
Delgado Enciso, Iván
Rodríguez León, Fernando
Jan, Virginia
Garzón Barrientos, Víctor Hugo
Ruiz Flores, Pablo
Espino Silva, Perla Karina Espino
Santa Cruz, Jorge Haro
Martínez Gregorio, Héctor
Rojas Jiménez, Ernesto Arturo
Romero Cruz, Luis Enrique
Méndez Catalá, Claudia Fabiola
Álvarez Gómez, Rosa María
Fragoso Ontiveros, Verónica
Alonso Herrera, Luis
Romieu, Isabelle
Terrazas, Luis Ignacio
Irasema Chirino, Yolanda
Frecha, Cecilia
Oliver, Javier
Vaca Paniagua, Felipe
Ochoa Díaz López, Héctor
Perdomo Lara, Sandra Janneth
- Tipo de recurso:
- Fecha de publicación:
- 2018
- Institución:
- Universidad El Bosque
- Repositorio:
- Repositorio U. El Bosque
- Idioma:
- eng
- OAI Identifier:
- oai:repositorio.unbosque.edu.co:20.500.12495/1585
- Palabra clave:
- Neoplasias de la mama
Neoplasias ováricas
Síndromes neoplásicos hereditarios
Genetic screening
Hereditary breast cancer
Massive parallel sequencing
- Rights
- License
- Attribution 4.0 International
Summary: | Hereditary breast and ovarian cancer syndrome (HBOC) represents 5–10% of all patients with breast cancer and is associated with high-risk pathogenic alleles in BRCA1/2 genes, but only for 25% of cases. We aimed to find new pathogenic alleles in a panel of 143 cancer-predisposing genes in 300 Mexican cancer patients with suspicion of HBOC and 27 high-risk patients with a severe family history of cancer, using massive parallel sequencing. We found pathogenic variants in 23 genes, including BRCA1/2. In the group of cancer patients 15% (46/300) had a pathogenic variant; 11% (33/300) harbored variants with unknown clinical significance (VUS) and 74% (221/300) were negative. The high-risk group had 22% (6/27) of patients with pathogenic variants, 4% (1/27) had VUS and 74% (20/27) were negative. The most recurrent mutations were the Mexican founder deletion of exons 9-12 and the variant p.G228fs in BRCA1, each found in 5 of 17 patients with alterations in this gene. Rare VUS with potential impact at the protein level were found in 21 genes. Our results show for the first time in the Mexican population a higher contribution of pathogenic alleles in other susceptibility cancer genes (54%) than in BRCA1/2 (46%), highlighting the high locus heterogeneity of HBOC and the necessity of expanding genetic tests for this disease to include broader gene panels. View Full-Text |
---|